Medicine
Cyramza 500 mg/50 mL injection
Cyramza 500 mg/50 mL injection is a prescription medicine containing Ramucirumab for intravenous use, marketed by Eli Lilly, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store vials in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original…
Key facts
- Active ingredient (INN)
- Ramucirumab
- Brand
- Cyramza
- Strength
- 500 mg/50 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 1 vial of 50 mL
- Marketing authorisation holder
- Eli Lilly
- Manufacturer
- Eli Lilly
- Origin register
- US FDA, United States
- Storage
- Store vials in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light until time of use. Do not freeze or shake the vial.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01FG02 Ramucirumab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 21 April 2014
- Identifiers
- RxCUI 1657775, 1657777, 1657780 +1DailyMed set ID c6080942-dee6-423e-b688-1272c2ae90d4NDC 0002-7678Application BLA125477
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-dose in 1 carton / 50 mL in 1 vial, single-dose | 0002-7678-01 | Eli Lilly | 21 April 2014 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Ramucirumab
Clinical summary
Ramucirumab is a vascular endothelial growth factor receptor 2 antagonist indicated as a single agent or in combination with paclitaxel, among other approved uses. It is available as injection for intravenous use. MedsAcross supplies Ramucirumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about RamucirumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- CYRAMZA prescribing information (Eli Lilly) · U.S. National Library of Medicine, DailyMed
- Cyramza: European public assessment report (EPAR) · European Medicines Agency
Need Cyramza 500 mg/50 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.